Verley Targets 2027 Launch of Animal-Free Whey for Lactose-Intolerant Populations
Verley established its U.S. operations in San Francisco and appointed Shayri Roychoudhury—former Perfect Day production lead—to oversee operations. The company achieved 50,000-litre production capacity and secured FDA approval for its FermWhey product line after initial GRAS status for two ingredients. Verley targets a mid-2027 launch of precision-fermented whey proteins, with an initial annual output of 1,000 tonnes and long-term ambitions of 5,000 tonnes. FermWhey Native 100 contains 40% more leucine than conventional whey protein isolate, potentially offering enhanced nutritional density.
This approach addresses a key need for lactose-intolerant individuals by providing animal-free dairy alternatives without requiring animal products. The FDA’s prior 'no questions' letter and Roychoudhury’s supply chain expertise signal readiness for commercial scale. However, the launch timeline remains approximate, and the 5,000-tonne target is a long-term aspiration—not current output.
Verley’s progress moves abundance by scaling a viable alternative for lactose-intolerant populations, who face limited access to dairy substitutes. If commercialized successfully, this could reduce reliance on animal-derived products while meeting nutritional needs without lactose. What to watch: FDA approval’s conditional link to commercial viability and whether Verley achieves its production targets amid scaling challenges. The source confirms no price reductions or population impact figures—only the product’s technical readiness and production milestones.
Source: Green Queen
Many Minded